Αρχική World News Adding Atezolizumab to mFOLFOX6 Improves DFS Among Patients with Stage III dMMR Colon Cancer World News Adding Atezolizumab to mFOLFOX6 Improves DFS Among Patients with Stage III dMMR Colon Cancer Από Ogkologos - 31 Μαρτίου, 2026 266 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ATOMIC study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR European Parliament Adopts Its Position on the Critical Medicines Act, Strengthening... 22 Ιανουαρίου, 2026 Immunotherapy Drugs Expand Treatment Options for Advanced Lung Cancer 27 Απριλίου, 2018 How to Maintain Your Sexual Health During and After Lung Cancer 10 Νοεμβρίου, 2020 Company Gives Cancer Patient a New HVAC System After Treatment and... 8 Μαρτίου, 2019 Φόρτωση περισσοτέρων HOT NEWS FDA Approves Tremelimumab in Combination with Durvalumab and Platinum-Based Chemotherapy for... How to Be Brave When Your Parent Has Cancer: A Kid’s... EMA Recommends Granting a Marketing Authorisation for Asciminib Telisotuzumab Vedotin Associated with Durable Responses in c-Met Protein–Overexpressing Non-Squamous EGFR-wild-type...